Hinge Bio specializes in leveraging its proprietary Flex-Hinge antibody platform to develop bispecific and multispecific antibodies.
Hinge Bio is a biotechnology company that specializes in leveraging its proprietary Flex-Hinge antibody platform to develop bispecific and multispecific antibodies. It features chemical ligation process technology that enables the production of therapeutic candidates with orders-of-magnitude improved affinity and specificity.
The company was founded in 2015 and headquartered in Burlingame, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 22, 2018 | Grant | $224.45K | 1 |
![]() |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Grant |